Rsk inhibitors and therapeutic uses thereof
CA 2488864 A1 · Owner: Xu, Yaming · Inventors: Hecht, Sidney M.; Xu, Yaming; Smith, Jeffrey A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition inhibition of Rsk by the , present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 12, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 12, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 12, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.